Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.